CHRISTINA WEISS: Open Payments
NPI 1184187999 · FORT WAYNE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$567 in 15 payments from 9 companies in 2025. Trend: 2023 $999 · 2024 $808 · 2025 $567
Food & beverage: $567
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $212 |
| Teva Pharmaceuticals USA, Inc. | 1 | $113 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $88 |
| Janssen Biotech, Inc. | 2 | $41 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $37 |
| GENZYME CORPORATION | 1 | $23 |
| Lilly USA, LLC | 1 | $21 |
| QOL Medical, LLC | 1 | $16 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
Products named: AUSTEDO XR, ENTYVIO, TREMFYA, XIFAXAN, EOHILIA, DUPIXENT, OMVOH, Sucraid.
Industry payments across IN — which companies pay providers there.
